Does Wegovy have a golden dose like Mounjaro does?

The myth: Wegovy has a definitive "best" dose the way Mounjaro does

The "golden dose" phrase started as shorthand in weight-management communities, not in clinical literature. The idea is that somewhere along the titration ladder there is a dose that delivers the most weight loss for most people with the least side-effect burden. For Mounjaro, the observation has some grounding: the six-dose schedule (2.5mg through to 15mg) gives clinicians and patients a relatively long runway, and trial data showed that the 10mg and 12.5mg doses already produced substantial average loss before the 15mg ceiling. Some people plateau at 10mg with good tolerance and their prescriber may stay there rather than titrate further.

Wegovy's schedule is shorter: 0.25mg, 0.5mg, 1.0mg, 1.7mg, then 2.4mg as the standard maintenance dose. There are fewer intermediate stops, so the phrase "golden dose" maps onto it less naturally. The 2.4mg maintenance dose is simply where most people end up if they tolerate the titration. Since January 2026, a 7.2mg dose has also been licensed in the UK, approved by the MHRA following evidence of around 20.7% average weight loss over 72 weeks at that level. That higher ceiling changes the picture somewhat, but it does not create a new intermediate "sweet spot" in the way Mounjaro's mid-ladder doses do.

So the myth is this: that both medicines work the same way and that a golden dose exists equally for each. If you want a closer look at how Wegovy and Mounjaro doses differ across their full titration schedules, that comparison can help clarify why the concept fits Mounjaro's structure far better, and applying it to Wegovy requires understanding a different titration philosophy, as our page on Mounjaro and Wegovy doses explores in detail.

Where Wegovy's 7.2mg dose fits into the picture

The MHRA approved the dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, making it the highest licensed semaglutide dose for weight management in the UK. In clinical trials, participants taking 7.2mg achieved average weight loss approaching the results seen with tirzepatide 15mg in SURMOUNT-1, closing a gap that had been the basis of most head-to-head comparisons. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, showed tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks, but that comparison was conducted before the 7.2mg dose became available. Full head-to-head data at 7.2mg versus tirzepatide 15mg does not yet exist at scale.

If any Wegovy dose earns the informal "golden" label going forward, 7.2mg is the candidate: it is the maximum, it has the strongest trial results for semaglutide in weight management, and it arrives in a single pen designed specifically for that dose. Whether it is right for a given patient is a separate question entirely. Starting dose remains 0.25mg regardless, titrated slowly upward. For detail on how the two medicines' dose ranges actually map onto each other, our page on Mounjaro-equivalent doses to Wegovy works through the comparison carefully.

It is also worth noting that availability of specific pen formats and doses is confirmed at consultation, not assumed. Novo Nordisk supply and individual clinical suitability both play a role.

How Mounjaro and Wegovy doses compare in practice

The table below sets out the key factual differences between the two titration schedules. Numbers are drawn from the respective SmPCs and NICE appraisals.

Our page covering how a Wegovy dose compares to Mounjaro goes into more detail on what these numbers mean practically for patients moving between the two medicines. For cost context specifically, the price difference between the two is covered separately.

What this means when you are deciding between the two

The question of whether Wegovy has a golden dose is, in practice, a proxy for a more useful question: which medicine, at which dose, is likely to work best for you? That cannot be answered by a comparison article. It depends on your BMI, your weight-related conditions, your history with either medicine, your tolerance of side effects and a handful of other factors a prescriber weighs during assessment.

What can be said plainly is this. Mounjaro's longer titration ladder gives clinicians more flexibility to find a dose that balances efficacy and tolerability for each person. Wegovy's shorter schedule is simpler in some ways, and the new 7.2mg option extends the ceiling meaningfully. Neither is universally better. The NICE appraisal of tirzepatide (TA1026) and the appraisal of semaglutide (TA875) both reflect that clinical context matters as much as the headline trial figures.

The tablet that sits on your kitchen worktop next to the kettle matters less than whether it was prescribed for the right reasons by someone who reviewed your full picture. At nume, a real prescriber reads your consultation before anything is dispensed. If you want to explore which treatment fits your situation, starting a free consultation is the right first step. Our clinical team reviews each case individually, and there is no obligation to proceed. More general context on the weight-loss medicines we work with is on our weight loss overview page.